. 2015 Sep 15;22(6):933–940. doi: 10.1530/ERC-15-0314
This work is licensed under a Table 2.
OS (data cutoff date, 13 June 2013)
| Patient population | SSA naïve | Previous SSAa | ||
|---|---|---|---|---|
| n (%) | Median OS, months (95% CI) | n (%) | Median OS, months (95% CI) | |
| Total | 41 (100) | 50.6 (36.4–NR) | 155 (100) | 33.5 (27.5–44.7) |
| By tumor location | ||||
| Foregut | 15 (37) | 36.4 (25.5–NR) | 17 (11) | 33.6 (16.7–NR) |
| Midgut | 24 (59) | NR (42.4–NR) | 119 (77) | 33.5 (27.5–49.4) |
| Hindgut | 2 (5) | NR (4.7–NR) | 19 (12) | 35.8 (15.4–48.9) |
SSA, somatostatin analogues; OS, overall survival; NR, not reached.
a
Includes patients who had received previous octreotide or lanreotide treatment.